BRUSSELS, June 25: Belgian drug developer Ablynx said on Monday its top drug, arthritis treatment ozoralizumab, had shown a benefit over its biggest rival in the 24 billion dollar market for this class of treatment.
It said patients did not become immune to the drug, a problem which can affect its biggest rival Humira, produced by US based Abbott Laboratories.
‘We believe that we now have the components of a much stronger and differentiating licensing package than we had previously,’ Ablynx Chief Executive Edwin Moses said in a statement.
Abbott Laboratories has said antibodies developed in about 5 per cent of adult rheumatoid arthritis patients who take Humira. (AGENCIES)
Follow our WhatsApp channel